Insurance lobbying group, America’s Health Insurance Plans (AHIP), recently named Matt Eyles as its next president and CEO beginning June 1. Eyles, currently AHIP’s chief operating officer, recently gave a statement about his priorities for the organization once he begins his tenure.
Insurance lobbying group, America’s Health Insurance Plans (AHIP), recently named Matt Eyles as its next president and CEO to take over for Marilyn Tavenner beginning June 1. Eyles, currently AHIP’s chief operating officer, recently gave a statement about his priorities for the organization once he begins his tenure.
“Looking ahead, it’s really addressing issues related to the affordability of healthcare and how we make it easier and simpler for consumers… we really want to see consumers have more affordable, lower premium options in 2019 that also provide comprehensive coverage,” said Eyles in a statement.
One way to tackle the affordability of healthcare and rising drug costs is through a robust biosimilars market, according to a blog post on AHIP’s website. Biologics and other specialty medications are the fastest growing component of prescription drug spending, rising between 11.3% and 17.7% in 2017 alone.
The post discusses 6 policy changes that would reduce drug prices and encourage biosimilar usage:
“We’re focused on things that would get some real competition into the marketplace," said Eyles. "The first thing in the short-term is getting the CREATES Act enacted, which would end some of the gaming around access to drug samples that really can’t be justified by any stretch. The second area is focusing on biosimilars and realizing the potential of biosimilars to drive cost and price savings in the market."
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.